Skip to main content
Publications
Juliao P, Wurst K, Pimenta JM, Gemzoe K, Landy H, Moody MA, Tilson H, Covington D, Moore T, Marino R, Gilbride J, Liu A, Meizlik P, Petri M. Belimumab use during pregnancy: interim results of the belimumab pregnancy registry. Birth Defects Res Part A Clin Mol Teratol. 2023 Jan 15;115(2):188-204. doi: 10.1002/bdr2.2091
Auclair D, Mansfield C, Fiala MA, Chari A, Cole CE, Kaufman JL, Orloff GJ, Siegel DS, Zonder JA, Mange B, Yesil J, Dalal M, Mikhael JR. Preferences and priorities for relapsed multiple myeloma treatments among patients and caregivers in the United States. Patient Prefer Adherence. 2022 Mar 1;2022(16):573-85. doi: 10.2147/PPA.S345906
Aletaha D, Husni ME, Merola JF, Ranza R, Bertheussen H, Lippe R, Young P, Cappelleri JC, Brown TM, Ervin C, Hsu M-A, Fallon L. Treatment mode preferences in psoriatic arthritis: a qualitative multi-country study. Patient Prefer Adherence. 2020 Jun 8;2020(14):949-61. doi: 10.2147/PPA.S242336
Taylor PC, Betteridge N, Brown TM, Woolcott J, Kivitz AJ, Zerbini C, Whalley D, Olayinka-Amao O, Chen C, Dahl P, Ponce de Leon D, Gruben D, Fallon L. Treatment mode preferences in rheumatoid arthritis: moving toward shared decision-making. Patient Prefer Adherence. 2020 Jan 20;14:119-31. doi: 10.2147/PPA.S220714
Epstein MM, Divine G, Chao CR, Wells KE, Feigelson HS, Scholes D, Roblin D, Yood MU, Engel LS, Taylor A, Fortuny J, Habel LA, Johnson CC. Statin use and risk of multiple myeloma: an analysis from the Cancer Research Network. Int J Cancer. 2017 Aug 1;141(3):480-7. doi: 10.1002/ijc.30745
Tennis P, Chan KA, Curkendall SN, Li DK, Mines D, Peterson C, Andrews EB, Calingaert B, Chen HY, Deshpande G, Everage N, Holick CN, Meyer NM, Nkhoma ET, Quinn S, Rothman KJ, Esposito DB. Topiramate use during pregnancy and major congenital malformations in multiple populations. Birth Defects Res Part A Clin Mol Teratol. 2015 Apr;103(4):269-75. doi: 10.1002/bdra.23357.
Hoyo C, Schildkraut JM, Murphy SK, Chow WH, Vaughan TL, Risch H, Marks JR, Jirtle RL, Calingaert B, Mayne S, Fraumeni, Jr. J, Gammon MD. IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. Int J Cancer. 2009 Dec 1;125(11):2673-8.
Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V, Marmol M, Gallardo E, Maria Auge J, Longaron R, Martinez-Fernandez A, Molina R, Castells A, Gascon P. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer. 2007 Sep 1;121(5):1066-71.
Fortuny J, Kogevinas M, Chang-Claude J, Gonzalez CA, Hours M, Jockel KH, Bolm-Audorff U, Lynge E, 't Mannetje A, Porru S, Ranft U, Serra C, Tzonou A, Wahrendorf J, Boffetta P. Tobacco, occupation and non-transitional-cell carcinoma of the bladder: an international case-control study. Int J Cancer. 1999 Jan 5;80(1):44-6. doi: 3.0.co;2-8">10.1002/(sici)1097-0215(19990105)80:1<44::aid-ijc9>3.0.co;2-8